ArticleZeitschrift fur Rheumatologie2026
[How often do patients with Sjögren's syndrome fulfil the activity criteria for immunomodulatory treatment?]
Article in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSjögren's disease belongs to the group of collagenoses, it is characterized by xerophthalmia and xerostomia and typically shows autoimmune phenomena in laboratory test parameters (mostly specific antibodies against cytoplasmic ribonucleoprotein complexes). So far there is no approved immunomodulatory treatment for Sjögren's disease but that may soon change. AIMS AND
methodsPatients with Sjögren's disease were prospectively and consecutively included in a descriptive single-center study to be assessed with the EULAR Sjögren's disease activity index (ESSDAI) and the EULAR Sjögren's disease patient reported index (ESSPRI).
resultsWithin a time period of 20 weeks during the first months of 2026 a total of 70 patients with Sjögren's disease were documented (62 with primary Sjögren's disease) of whom 68 fulfilled the classification criteria for Sjögren's disease (97%). The mean age was 60.5 years (range 24-84 years), 98% were female and the mean duration of sicca symptoms was 9.7±8.2 years (range 1-25 years). Almost two thirds of the patients regularly used eyedrops and 25% were treated with hydroxychloroquine and 12% with methotrexate. The mean ESSPRI score was 5.4 and the mean ESSDAI was 9.7 points. In the former the focus was on the sicca symptoms (6.3), followed by tiredness (5.7) and pain (5). For the ESSDAI joint pain (63%) was most frequently reported, followed by gland-related (43%), constitutional symptoms (13%) and lymphadenopathy (8%), whereas for laboratory parameters biological (44%) and hematological (15%) abnormalities were reported. Overall, 42 patients had an ESSPRI score ≥5 (60.0%) and 34 had an ESSDAI score ≥5 (48.6%). Only 13 female patients had a score ≤5 in both ESSDAI and ESSPRI (18.6%). Of the patients 20 (28.6%) had an ESSPRI score ≥5 and an ESSDAI score ≥5. DISCUSSION: This observational study shows that a not insubstantial number of patients with Sjögren's disease would fulfil the criteria for immunomodulatory treatment.
Indexed as
Identifiers
42814142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.